ArticleHealth science reports2025
Drug-Related Side Effects and Contributing Risk Factors in Children With Congenital Heart Disease: A Cross-Sectional Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Preferences for Internet Plus Nursing Services Among Nurses and Patients in China: A Systematic Review of Discrete Choice Experiments.Journal of nursing management · 2026Pooled it
- Beyond Survival: Parents' Experiences and Healthcare Professionals' Perspectives on Family-Centred Care for Children with Congenital and Acquired Heart Disease: A Qualitative Study.Healthcare (Basel, Switzerland) · 2026Article
- Stakeholder Perspectives on Health System Readiness for Integrating Artificial Intelligence into Public Health in Saudi Arabia.Healthcare (Basel, Switzerland) · 2026Article
- Demand analysis of knowledge regarding cardiac rehabilitation among parents of children with congenital heart disease after surgery based on the Kano model.BMC pediatrics · 2026Article
- A clinical decision support system for predicting drug-related adverse effects in pediatric patients with congenital heart disease: Development and retrospective evaluation.The Journal of international medical research · 2026Article
- Polypharmacy and Drug Interaction Risk in Children and Adolescents with Congenital Heart Defects: Insights from a Nationwide Survey.Journal of clinical medicine · 2026Article
- Remdesivir in COVID-19: A Focus on Pediatric Cardiac Patients.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Effects of remimazolam on hemodynamics in children with congenital heart disease undergoing cardiac catheterization.Frontiers in pharmacology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Children with congenital heart disease (CHD) often require complex pharmacotherapy for symptom management and complication prevention. However, their unique physiological profiles increase vulnerability to drug-related side effects. This study aimed to identify specialists' perspectives on drug-related side effects and associated risk factors in pediatric CHD patients. Methods: A cross-sectional study was conducted in 2024 involving 20 pediatric cardiologists and pediatric cardiology fellows. Data were collected using two 5-point Likert scale questionnaires assessing commonly prescribed drugs, observed side effects, and associated risk factors in pediatric CHD patients. Data were analyzed using student's Results: According to the findings, the most frequent side effects linked to common medications were hypokalemia (Furosemide; 4.5 ± 0.69), apnea (Prostaglandin E1; 4.5 ± 0.62), and bradycardia (Sotalol; 4.41 ± 0.51). Dosage and polypharmacy emerged as major risk factors, particularly for drugs like Digoxin and Heparin. Younger age, underlying health conditions, and specific drug combinations also increased the risk of side effects. The Conclusions: The findings emphasize the need for a personalized approach to pharmacotherapy in pediatric CHD patients, requiring careful drug selection, dose optimization, and enhanced monitoring strategies. Drug-related side effects highlight the importance of implementing clinical decision support systems, routine therapeutic drug monitoring, and individualized dosing adjustments to mitigate risks. Future research should prioritize longitudinal studies to establish causality relationships, optimize treatment protocols, and improve medication safety in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.